Board of Directors
The GI Dynamics board is committed to carrying out our mission of improving the lives of people suffering from the global epidemics of type 2 diabetes and obesity through the development and commercialization of breakthrough treatments.
Daniel J. Moore (Chairman)
Daniel Moore is Chairman of the Board for LivaNova [NASDAQ: LIVN] and also chairs the board of BrainScope Company, Inc. Mr. Moore previously held the position as president and chief executive officer of Cyberonics [NASDAQ: CYBX] from 2007 to 2015, when the company merged with Sorin to form LivaNova. Mr. Moore joined Cyberonics after 18 years at Boston Scientific [NYSE: BSX] where he was the president of InterContinental. He also serves on the boards of the Epilepsy Foundation of America, BioHouston and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering.
Prior company boards include TriVascular [NASDAQ: TRIV] which was sold to Endologix and Topera which was sold to Abbott. He also served on the boards of the Medical Device Manufacturers Association (past-Chair), Medical Device Innovation Consortium, the Epilepsy Foundation of Texas (past- Chair) and Smiling Kids Inc.
Dr. Oern Stuge
Dr. Oern Stuge, MD, MBA, brings significant experience in medical devices and specifically in type 2 diabetes and obesity. He has also lead successful clinical development programs and global commercialization efforts and has held executive and board positions with numerous medical device companies over the past 30 years. As director, he has helped lead several successful company exits, raised significant capital and launched an IPO.
Timothy J. Barberich
Timothy Barberich has nearly 40 years’ experience in pharmaceutical and medical device companies, in technical, sales, marketing and management positions, including chief executive officer and chairman of the board. Mr. Barberich is a founder and former chief executive officer and chairman of Sepracor, Inc., now known as Sunovion Pharmaceuticals, a research-based pharmaceutical company which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009.
Mr. Barberich is currently chairman and chief executive officer of BioNevia Pharmaceuticals, Inc. He also serves on the board of directors of HeartWare International, Inc. [NASDAQ: HTWR], Verastem Inc. [NASDAQ: VSTM], Tokai Pharmaceuticals [NASDAQ: TKAI], Neurovance, Inc, and Mirimmune, Inc.
Juliet Thompson has advised and raised capital for healthcare companies for more than 20 years and founded Code Securities, a healthcare investment banking firm that was sold to Nomura. In addition to GI Dynamics, Juliet also serves as NED for Nexstim Limited, NED for Novacyt SA, and is the chair of Premier Veterinary Group Plc.